Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

AL102-501

13 evidence topics · 2 sources

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-501”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2024-11-11”
Primary completion (actual)“2024-12-30”
Study completion (actual)“2025-05-07”
First posted“2024-11-07”
Last update posted“2025-05-11”
Site“Celerion”; “Tempe”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Keywords“Drug-Drug Interaction”; “Pharmacokinetics”
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“22”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
  • The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
  • The registry record does not state the varegacestat dose given.